MTA-Uncompetitive PRMT5 Compounds for MTAP-Deleted Cell Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PRMT5 inhibitors lack selectivity for MTAP-deleted cancer cell lines due to their mechanisms of action, which are either SAM-uncompetitive or SAM-competitive, failing to leverage the accumulation of MTA caused by MTAP-deletion.
Innovation Solution
Development of PRMT5 inhibitors that bind in an MTA-uncompetitive manner, leveraging the accumulation of MTA to selectively target MTAP-deleted cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PRMT5 inhibitors with SAM-uncompetitive or SAM-competitive mechanisms are used, then PRMT5 inhibition is achieved, but selectivity for MTAP-deleted cancer cells is lost
Solution Approach 1:
The patent changes the binding mechanism parameter from SAM-uncompetitive or SAM-competitive to MTA-uncompetitive binding. This parameter change allows the inhibitor to specifically recognize and bind to PRMT5 in the context of MTA accumulation, which occurs only in MTAP-deleted cells, thereby achieving both PRMT5 inhibition and selective targeting of MTAP-deleted cancer cells
Solution Approach 2:
The patent uses MTA as an intermediary molecule. Instead of directly targeting PRMT5 with conventional inhibitors, the invention designs an inhibitor that binds uncompetitively with MTA, leveraging MTA as a mediator to achieve selective inhibition. The accumulated MTA in MTAP-deleted cells acts as a unique identifier that enables selective drug binding and inhibition of PRMT5 activity specifically in these cancer cells
2Reliability
If conventional PRMT5 inhibitors are developed, then PRMT5 activity is inhibited, but the accumulation of MTA in MTAP-deleted cells is not leveraged
Solution Approach 1:
The invention changes the binding mechanism parameter from conventional SAM-based inhibition to MTA-uncompetitive binding. This allows the drug to adapt to and leverage the unique metabolic state of MTAP-deleted cells (MTA accumulation) rather than simply inhibiting PRMT5 activity in all cells regardless of their metabolic state
Solution Approach 2:
The patent enables the drug to self-select its target cells through the MTA-uncompetitive binding mechanism. The accumulated MTA in MTAP-deleted cells serves as a built-in selection mechanism that automatically directs the inhibitor to the appropriate cancer cells without requiring external selection criteria or complex delivery systems
Data Source
AI summary
Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof: wherein X1, X2, X3, X4, X5, A, L, R1, R2, R5, m and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.